Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Fall Clinical Dermatology Conference for PAs and NPs Recap: Day 1
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Dermatology HCPs Previously Underestimated Patient Burden of Seborrheic Dermatitis
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Plan Your Trip: What to do While Visiting Orlando
Topical Skin Care Probiotics Made With New Technology Yield Numerous Benefits